Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

fludarabine 3aldesleukin 3Specimen Handling 3Cyclophosphamide 3Sunitinib 2Fluorouracil 2Bevacizumab 2trastuzumab deruxtecan 1sodium propionate 1semaglutide 1repotrectinib 1patritumab deruxtecan 1isosorbide-5-mononitrate 1fludarabine phosphate 1dehydroftorafur 1Ultrasonography 1Tretinoin 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Radiosurgery 1Psilocybin 1Positron-Emission Tomography 1Photography 1Pemetrexed 1Oxaliplatin 1Oviposition 1Memantine 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × IDRX-42 × 30 days × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡